Holen Sie sich die Stockscreener-App
17.40
0.00%
0.00
Vorhandelsmarkt:
17.25
-0.15
-0.86%
Schlusskurs vom Vortag:
$17.40
Offen:
$17.03
24-Stunden-Volumen:
49,672
Relative Volume:
0.70
Marktkapitalisierung:
$31.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.85M
KGV:
-56.13
EPS:
-0.31
Netto-Cashflow:
$-3.95M
1W Leistung:
+8.82%
1M Leistung:
+7.61%
6M Leistung:
+169.77%
1J Leistung:
+12.62%
1-Tages-Spanne:
$17.03
$18.80
1-Wochen-Bereich:
$15.56
$18.80
52-Wochen-Spanne:
$5.40
$32.55
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Firmenname
Cadrenal Therapeutics Inc
Sektor
Branche
Telefon
904-300-0701
Adresse
822 A1A NORTH, PONTE VEDRA
Vergleichen Sie CVKD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
17.40 | 31.02M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-18 | Eingeleitet | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Aktie (CVKD) Neueste Nachrichten
Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals
Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily
Ponte Vedra biotech firm opens the Nasdaq - The Business Journals
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Business Wire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Large Growth in Short Interest - Defense World
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire
(CVKD) Investment Report - Stock Traders Daily
AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 11.6% – Time to Buy? - Defense World
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online
CVKDCadrenal Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Yahoo Finance
(CVKD) Trading Report - Stock Traders Daily
What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings? - Defense World
CVKD: Recent Financings Raise $9.8 Million… - MSN
Kairos Pharma approved to dual list on Upstream - MSN
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - StockTitan
(CVKD) Technical Data - Stock Traders Daily
ARMISTICE CAPITAL, LLC Acquires New Stake in Cadrenal Therapeuti - GuruFocus.com
Cadrenal's Tecarfarin Shows Promise for LVAD Patients in Key Medical Congress Data | CVKD Stock News - StockTitan
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS - PR Newswire
Cadrenal shares gain; analyst highlights Buy rating and key LVAD trial advancements - Investing.com Canada
Cadrenal Therapeutics Provides Third-Quarter Corporate Update - Defense World
Cadrenal Therapeutics Advances Tecarfarin Development - TipRanks
Cadrenal Therapeutics Raises $9.8M, Advances Unique Anticoagulant Drug Development | CVKD Stock News - StockTitan
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - StockTitan
Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Yahoo Finance
(CVKD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cadrenal Therapeutics secures $5.1 million in share sale - Investing.com
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin - TipRanks
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM - PR Newswire
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Drops By 7.2% - MarketBeat
Renaissance Technologies LLC Reduces Stock Position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) - MarketBeat
Long Term Trading Analysis for (CVKD) - Stock Traders Daily
Jacksonville stocks rise as market hits record highs - Jacksonville Daily Record
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Rises By 22.8% - MarketBeat
Cadrenal Therapeutics Inc (CVKD-Q) QuotePress Release - The Globe and Mail
Where are the Opportunities in (CVKD) - Stock Traders Daily
Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy - TipRanks
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference - Kilgore News Herald
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Forecasted to Earn Q3 2024 Earnings of ($2.18) Per Share - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Trading Down 4.1% - Defense World
WATCH LIVE: Fed Chair Jerome Powell speaks after a 50bp interest rate cut - Investing.com
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data - MSN
Cadrenal Therapeutics (CVKD) Stock Rallies In After-Market Trading Ahead Of Regulatory Meeting - Stocks Telegraph
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - MarketBeat
Finanzdaten der Cadrenal Therapeutics Inc-Aktie (CVKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):